Viracta Therapeutics (VIRX) Competitors $0.02 +0.00 (+1.25%) As of 07/3/2025 12:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIRX vs. VRAX, ADIL, OGEN, ENTO, SLRX, PTN, AWH, ALZN, PWUP, and ONCOShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Virax Biolabs Group (VRAX), Adial Pharmaceuticals (ADIL), Oragenics (OGEN), Entero Therapeutics (ENTO), Salarius Pharmaceuticals (SLRX), Palatin Technologies (PTN), Aspira Women's Health (AWH), Alzamend Neuro (ALZN), PowerUp Acquisition (PWUP), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Its Competitors Virax Biolabs Group Adial Pharmaceuticals Oragenics Entero Therapeutics Salarius Pharmaceuticals Palatin Technologies Aspira Women's Health Alzamend Neuro PowerUp Acquisition Onconetix Virax Biolabs Group (NASDAQ:VRAX) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership. Do institutionals and insiders hold more shares of VRAX or VIRX? 8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 10.7% of Viracta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to VRAX or VIRX? In the previous week, Virax Biolabs Group's average media sentiment score of 0.00 equaled Viracta Therapeutics'average media sentiment score. Company Overall Sentiment Virax Biolabs Group Neutral Viracta Therapeutics Neutral Which has more risk & volatility, VRAX or VIRX? Virax Biolabs Group has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Do analysts rate VRAX or VIRX? Virax Biolabs Group presently has a consensus target price of $3.00, suggesting a potential upside of 246.82%. Viracta Therapeutics has a consensus target price of $1.75, suggesting a potential upside of 10,702.47%. Given Viracta Therapeutics' higher probable upside, analysts clearly believe Viracta Therapeutics is more favorable than Virax Biolabs Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Viracta Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is VRAX or VIRX more profitable? Virax Biolabs Group's return on equity of 0.00% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A Viracta Therapeutics N/A -1,899.61%-114.21% Which has stronger valuation & earnings, VRAX or VIRX? Virax Biolabs Group has higher revenue and earnings than Viracta Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$10K375.41-$6.06MN/AN/AViracta TherapeuticsN/AN/A-$51.06M-$1.10-0.01 SummaryVirax Biolabs Group beats Viracta Therapeutics on 7 of the 9 factors compared between the two stocks. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$644K$798.01M$5.53B$9.02BDividend YieldN/A4.84%5.22%3.99%P/E Ratio-0.011.3727.7020.25Price / SalesN/A230.41419.56119.26Price / CashN/A23.4426.2128.59Price / Book0.056.328.035.65Net Income-$51.06M-$27.99M$3.18B$249.15M7 Day PerformanceN/A2.32%2.88%2.91%1 Month PerformanceN/A9.07%1.67%4.11%1 Year PerformanceN/A11.51%34.39%20.98% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics2.1113 of 5 stars$0.02+1.3%$1.75+10,702.5%-96.6%$644KN/A-0.0120Gap DownVRAXVirax Biolabs Group2.854 of 5 stars$0.76-4.3%$3.00+294.7%-29.1%$2.57M$160K0.005Gap DownADILAdial Pharmaceuticals2.3314 of 5 stars$0.26+7.2%$8.00+2,941.8%-68.9%$2.56MN/A-0.1820Gap DownOGENOragenics0.2176 of 5 stars$3.57-2.3%N/A-95.1%$2.55M$40K-0.505ENTOEntero TherapeuticsN/A$0.50-5.8%N/A-62.2%$2.53MN/A0.009Gap DownSLRXSalarius Pharmaceuticals0.703 of 5 stars$1.05-8.7%N/A-60.9%$2.45MN/A-0.2220Positive NewsPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's Health0.909 of 5 stars$0.08-12.5%$5.50+6,607.3%-92.6%$2.44M$9.18M-0.07110High Trading VolumeALZNAlzamend Neuro2.414 of 5 stars$2.95-3.0%$180.00+6,001.7%-91.6%$2.43MN/A0.004Positive NewsGap UpPWUPPowerUp AcquisitionN/A$0.29-8.8%N/A-97.4%$2.25MN/A0.00N/AGap DownHigh Trading VolumeONCOOnconetix0.2899 of 5 stars$4.03-3.8%N/A-99.1%$2.23M$2.52M0.0012 Related Companies and Tools Related Companies VRAX Alternatives ADIL Alternatives OGEN Alternatives ENTO Alternatives SLRX Alternatives PTN Alternatives AWH Alternatives ALZN Alternatives PWUP Alternatives ONCO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
